Form 4: Redmile Group Converts Preferred Stock in Fate Therapeutics, Adjusts Ownership

Redmile Group, a significant shareholder in Fate Therapeutics, converted preferred stock to common stock and adjusted its reported holdings due to a change in investment advisory roles.

Summary

• Redmile Group, a major shareholder of Fate Therapeutics, converted 6,022 shares of Class A Convertible Preferred Stock into 30,110 shares of common stock on December 12, 2024.
• This conversion was based on a ratio of one preferred share converting into five common shares.
• The conversion was executed by a private investment vehicle managed by Redmile.
• Redmile's total beneficial ownership of Fate Therapeutics common stock is now reported as 12,827,946 shares.
• Redmile no longer manages a sub-advised account that held 382,552 shares of Fate Therapeutics, and these shares are not included in their reported holdings.
• Jeremy Green, a principal of Redmile, also disclaims beneficial ownership of the 382,552 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction and adjustment of holdings by a major shareholder, indicating a neutral to slightly positive sentiment due to continued significant ownership.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Fate Therapeutics.
• Redmile's continued significant ownership indicates ongoing confidence in the company.

Risks

• Changes in ownership percentages could potentially impact the influence of major shareholders.
• The disclaimer of beneficial ownership of 382,552 shares could indicate a shift in Redmile's investment strategy.

Management Comments

• Mr. Michael Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates.
• The Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.

Industry Context

This filing reflects routine adjustments in ownership and investment management within the biotechnology sector, where significant institutional investors often hold large positions and may adjust their holdings based on various factors.

Comparison to Industry Standards

• Similar filings are common among biotech companies with significant institutional ownership, such as those held by entities like Baker Bros. Advisors or RA Capital Management.
• The conversion of preferred stock to common stock is a standard practice to simplify capital structures, similar to actions taken by other companies in the sector.
• The adjustment of reported holdings due to changes in investment advisory roles is also a common occurrence, reflecting the dynamic nature of institutional investment.

Stakeholder Impact

• The conversion of preferred stock to common stock may have a minor impact on the overall share structure.
• The change in reported holdings may be of interest to other shareholders, but is not expected to have a significant impact on the company's operations.

Key Dates

Keywords

Redmile Group, Fate Therapeutics, Class A Convertible Preferred Stock, Common Stock, Beneficial Ownership, Conversion, Investment Management, Shareholder